|
1
|
Bazan JF: Haemopoietic receptors and
helical cytokines. Immunol Today. 11:350–354. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Elliott S and Sinclair AM: The effect of
erythropoietin on normal and neoplastic cells. Biologics.
6:163–189. 2012.PubMed/NCBI
|
|
3
|
Fraser M, Bai T and Tsang BK: Akt promotes
cisplatin resistance in human ovarian cancer cells through
inhibition of p53 phosphorylation and nuclear function. Int J
Cancer. 122:534–546. 2008. View Article : Google Scholar
|
|
4
|
Richmond TD, Chohan M and Barber DL:
Turning cells red: Signal transduction mediated by erythropoietin.
Trends Cell Biol. 15:146–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koury MJ and Bondurant MC: The molecular
mechanism of erythropoietin action. Eur J Biochem. 210:649–663.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Masuda S, Nagao M, Takahata K, Konishi Y,
Gallyas F Jr, Tabira T and Sasaki R: Functional erythropoietin
receptor of the cells with neural characteristics. Comparison with
receptor properties of erythroid cells J Biol Chem.
268:11208–11216. 1993.
|
|
7
|
Anagnostou A, Liu Z, Steiner M, Chin K,
Lee ES, Kessimian N and Noguchi CT: Erythropoietin receptor mRNA
expression in human endothelial cells. Proc Natl Acad Sci USA.
91:3974–3978. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Westenfelder C, Biddle DL and Baranowski
RL: Human, rat, and mouse kidney cells express functional
erythropoietin receptors. Kidney Int. 55:808–820. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ogilvie M, Yu X, Nicolas-Metral V, Pulido
SM, Liu C, Ruegg UT and Noguchi CT: Erythropoietin stimulates
proliferation and interferes with differentiation of myoblasts. J
Biol Chem. 275:39754–39761. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abhold E, Rahimy E, Wang-Rodriguez J,
Blair KJ, Yu MA, Brumund KT, Weisman RA and Ongkeko WM: Recombinant
human erythropoietin promotes the acquisition of a malignant
phenotype in head and neck squamous cell carcinoma cell lines in
vitro. BMC Res Notes. 4:5532011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lopez TV, Lappin TR, Maxwell P, Shi Z,
Lopez-Marure R, Aguilar C and Rocha-Zavaleta L: Autocrine/paracrine
erythropoietin signalling promotes JAK/STAT-dependent proliferation
of human cervical cancer cells. Int J Cancer. 129:2566–2576. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pérès EA, Valable S, Guillamo JS, Marteau
L, Bernaudin JF, Roussel S, Lechapt-Zalcman E, Bernaudin M and
Petit E: Targeting the erythropoietin receptor on glioma cells
reduces tumour growth. Exp Cell Res. 317:2321–2332. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wu P, Zhang N, Wang X, Zhang C, Li T, Ning
X and Gong K: The erythropoietin/erythropoietin receptor signaling
pathway promotes growth and invasion abilities in human renal
carcinoma cells. PLoS One. 7:e451222012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou B, Damrauer JS, Bailey ST, Hadzic T,
Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, et al:
Erythropoietin promotes breast tumorigenesis through
tumor-initiating cell self-renewal. J Clin Invest. 124:553–563.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arcasoy MO: Non-erythroid effects of
erythropoietin. Haematologica. 95:1803–1805. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Debeljak N, Solár P and Sytkowski AJ:
Erythropoietin and cancer: The unintended consequences of anemia
correction. Front Immunol. 5:5632014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schnitt SJ: Classification and prognosis
of invasive breast cancer: From morphology to molecular taxonomy.
Mod Pathol. 23(Suppl 2): S60–S64. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Anderson WF, Chatterjee N, Ershler WB and
Brawley OW: Estrogen receptor breast cancer phenotypes in the
Surveillance, Epidemiology, and End Results database. Breast Cancer
Res Treat. 76:27–36. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ali S and Coombes RC: Endocrine-responsive
breast cancer and strategies for combating resistance. Nat Rev
Cancer. 2:101–112. 2002. View
Article : Google Scholar
|
|
20
|
Jensen EV and Jordan VC: The estrogen
receptor: A model for molecular medicine. Clin Cancer Res.
9:1980–1989. 2003.PubMed/NCBI
|
|
21
|
Jordan VC and Koerner S: Tamoxifen (ICI
46,474) and the human carcinoma 8S oestrogen receptor. Eur J
Cancer. 11:205–206. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen H, Tritton TR, Kenny N, Absher M and
Chiu JF: Tamoxifen induces TGF-beta 1 activity and apoptosis of
human MCF-7 breast cancer cells in vitro. J Cell Biochem. 61:9–17.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ellis PA, Saccani-Jotti G, Clarke R,
Johnston SR, Anderson E, Howell A, A'Hern R, Salter J, Detre S,
Nicholson R, et al: Induction of apoptosis by tamoxifen and ICI
182780 in primary breast cancer. Int J Cancer. 72:608–613. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mabuchi S, Ohmichi M, Kimura A, Ikebuchi
Y, Hisamoto K, Arimoto-Ishida E, Nishio Y, Takahashi K, Tasaka K
and Murata Y: Tamoxifen inhibits cell proliferation via
mitogen-activated protein kinase cascades in human ovarian cancer
cell lines in a manner not dependent on the expression of estrogen
receptor or the sensitivity to cisplatin. Endocrinology.
145:1302–1313. 2004. View Article : Google Scholar
|
|
25
|
Jordan VC: Tamoxifen (ICI46,474) as a
targeted therapy to treat and prevent breast cancer. Br J
Pharmacol. 147(Suppl 1): S269–S276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hopp TA and Fuqua SA: Estrogen receptor
variants. J Mammary Gland Biol Neoplasia. 3:73–83. 1998. View Article : Google Scholar
|
|
27
|
Milani A, Geuna E, Mittica G and Valabrega
G: Overcoming endocrine resistance in metastatic breast cancer:
Current evidence and future directions. World J Clin Oncol.
5:990–1001. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Viedma-Rodríguez R, Baiza-Gutman L,
Salamanca-Gómez F, Diaz-Zaragoza M, Martínez-Hernández G, Ruiz
Esparza-Garrido R, Velázquez-Flores MA and Arenas-Aranda D:
Mechanisms associated with resistance to tamoxifen in estrogen
receptor-positive breast cancer (Review). Oncol Rep. 32:3–15.
2014.PubMed/NCBI
|
|
29
|
Clark AS, West K, Streicher S and Dennis
PA: Constitutive and inducible Akt activity promotes resistance to
chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol
Cancer Ther. 1:707–717. 2002.PubMed/NCBI
|
|
30
|
Larsson AM, Jirström K, Fredlund E,
Nilsson S, Rydén L, Landberg G and Påhlman S: Erythropoietin
receptor expression and correlation to tamoxifen response and
prognosis in breast cancer. Clin Cancer Res. 15:5552–5559. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Van de Sompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol.
3:Research0034. 2002.
|
|
32
|
Volgger B, Kurz K, Zöschg K, Theurl I,
Ciresa-König A, Marth C and Weiss G: Importance of erythropoetin
receptor expression in tumour tissue for the clinical course of
breast cancer. Anticancer Res. 30:3721–3726. 2010.PubMed/NCBI
|
|
33
|
Trošt N, Hevir N, Rižner TL and Debeljak
N: Correlation between erythropoietin receptor(s) and estrogen and
progesterone receptor expression in different breast cancer cell
lines. Int J Mol Med. 31:717–725. 2013.
|
|
34
|
Reinbothe S, Larsson AM, Vaapil M, Wigerup
C, Sun J, Jögi A, Neumann D, Rönnstrand L and Påhlman S:
EPO-independent functional EPO receptor in breast cancer enhances
estrogen receptor activity and promotes cell proliferation. Biochem
Biophys Res Commun. 445:163–169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shi Z, Hodges VM, Dunlop EA, Percy MJ,
Maxwell AP, El-Tanani M and Lappin TR: Erythropoietin-induced
activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways
promotes malignant cell behavior in a modified breast cancer cell
line. Mol Cancer Res. 8:615–626. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Simoncini T, Genazzani AR and De Caterina
R: Towards a molecular understanding of the atheroprotective
effects of estrogens: A review of estrogen effects on endothelial
activation. Ital Heart J. 1:104–107. 2000.PubMed/NCBI
|
|
38
|
Kutuk O, Arisan ED, Tezil T, Shoshan MC
and Basaga H: Cisplatin overcomes Bcl-2-mediated resistance to
apoptosis via preferential engagement of Bak: Critical role of
Noxa-mediated lipid peroxidation. Carcinogenesis. 30:1517–1527.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu
X and Acs G: RNA interference-mediated inhibition of erythropoietin
receptor expression suppresses tumor growth and invasiveness in
A2780 human ovarian carcinoma cells. Am J Pathol. 174:1504–1514.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
McGuire WL: Current status of estrogen
receptors in human breast cancer. Cancer. 36:638–644. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Michalides R, Griekspoor A, Balkenende A,
Verwoerd D, Janssen L, Jalink K, Floore A, Velds A, van't Veer L
and Neefjes J: Tamoxifen resistance by a conformational arrest of
the estrogen receptor alpha after PKA activation in breast cancer.
Cancer Cell. 5:597–605. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Esslimani-Sahla M, Simony-Lafontaine J,
Kramar A, Lavaill R, Mollevi C, Warner M, Gustafsson JA and
Rochefort H: Estrogen receptor beta (ER beta) level but not its ER
beta cx variant helps to predict tamoxifen resistance in breast
cancer. Clin Cancer Res. 10:5769–5776. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Campbell RA, Bhat-Nakshatri P, Patel NM,
Constantinidou D, Ali S and Nakshatri H: Phosphatidylinositol
3-kinase/AKT-mediated activation of estrogen receptor alpha: A new
model for anti-estrogen resistance. J Biol Chem. 276:9817–9824.
2001. View Article : Google Scholar : PubMed/NCBI
|
